<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962442</url>
  </required_header>
  <id_info>
    <org_study_id>AAH-LYSO</org_study_id>
    <nct_id>NCT00962442</nct_id>
  </id_info>
  <brief_title>N-Acetylcysteine in Severe Acute Alcoholic Hepatitis</brief_title>
  <official_title>N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute alcoholic hepatitis (AAH) is the most severe form of alcoholic liver disease (ALD) and
      is associated with a high risk of dying in the short term. Corticosteroids are generally
      recommended in patients with severe AAH, but its use is still controverted and
      contraindicated in case of active infection or gastrointestinal bleeding. Therefore,
      alternative therapeutic options are needed.Ethanol consumption results in the depletion of
      endogenous antioxidant capabilities and patients with ALD have evidence of antioxidant
      deficiencies.Due to its effects on glutathion stores restoration and as such the limitation
      of the oxidative stress and its good tolerance and safety profile, N-acetylcysteine (NAC) is
      an attractive agent for the treatment of AAH.In this context, we hypothesized that NAC might
      be beneficial in severe AAH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six months survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of infections, clinical and biological parameters</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>nutritional support + N-Acétylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nutritional support + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>300 mg/kg for 14 days, intravenously</description>
    <arm_group_label>nutritional support + N-Acétylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Glucosé 5% perfusion for 14 days, intravenously</description>
    <arm_group_label>nutritional support + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven alcoholic hepatitis

          -  Severe disease defined by a Maddrey score superior to 32

        Exclusion Criteria:

          -  Neoplastic disease compromising 6 months survival

          -  HIV patients

          -  Hepatorenal syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2009</study_first_submitted>
  <study_first_submitted_qc>August 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2009</study_first_posted>
  <last_update_submitted>August 19, 2009</last_update_submitted>
  <last_update_submitted_qc>August 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Olivier Le Moine, MD, PhD</name_title>
    <organization>Erasme University Hospital</organization>
  </responsible_party>
  <keyword>alcoholic hepatitis</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>enteral nutrition</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>severe acute alcoholic hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

